

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-12 (Cancelled).

13(Currently amended). A method for preparing a composition for treating a viral infection, comprising:

collecting lymphocytes from a ~~virally-infected~~ patient contracting said viral infection; and

culturing said lymphocytes in a culture medium that is prepared for culturing in vitro and comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate in vitro said lymphocytes; and

obtaining proliferated and activated lymphocytes, which are effective against said viral ~~infections~~ infection, from said lymphocyte culture,

with the proviso that said ~~virally-infected~~ patient is not a cytomegalovirus-infected patient, said viral infection is not a cytomegalovirus infection, and said culture medium prepared for culturing in vitro does not include a specific antigen for said viral infection.

14(Currently amended). A method for treating a viral infection, ~~said method~~ comprising:

collecting lymphocytes from a ~~virally infected~~ patient contracting said viral infection;

culturing said lymphocytes in a culture medium that is prepared for culturing in vitro and comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said lymphocytes; and

administering said activated lymphocytes, which are effective against said viral infections ~~infection~~, to said patient contracting said viral infection from which said lymphocytes were derived,

with the proviso that said viral infection is not a cytomegalovirus infection and that said culture medium prepared for culturing in vitro does not include a specific antigen for said viral infection.

Claims 15-18 (Cancelled).

19(Currently amended). The method according to claim 13, wherein said *in vitro* proliferated and activated lymphocytes are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution for administration to ~~said~~ a patient contracting said viral infection.

20(Previously presented). The method according to claim 19, wherein a protein is added to said cell-suspended solution.

21(Previously presented). The method according to claim 20, wherein said protein is human albumin.

22(Previously presented). The method according to claim 13, wherein said culture medium further comprises cytokines.

23(Currently amended). The method according to claim 14, wherein said *in vitro* activated lymphocytes are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient contracting said viral infection.

24(Previously presented). The method according to claim 23, wherein a protein is added to said cell-suspended solution.

25(Previously presented). The method according to claim 24, wherein said protein is human albumin.

26(Currently amended). The method according to claim 23, wherein said ~~activated lymphocytes having a~~ cell-suspended solution has an activated lymphocyte cell concentration in the range of 1×10^4 parts/lit. parts/liter to 1×10^8 parts/lit. are

parts/liter and is administered to the same patient contracting
said viral infection~~at a time.~~

27(Previously presented). The method according to claim 14, wherein said culture medium further comprises cytokines.

Claims 28-30 (Cancelled).

31(Previously presented). The method according to claim 13, wherein said viral infection is an Epstein-Barr viral infection.

32(Previously presented). The method according to claim 14, wherein said patient is virally infected, immunodeficient or immunosuppressed due to an Epstein-Barr viral infection.

Claim 33 (Cancelled).

34(Previously presented). The method according to claim 13, wherein said viral infection is a herpes simplex viral infection.

Claim 35 (Cancelled).

36(Previously presented). The method according to claim 13, wherein the activated lymphocytes are T-lymphocytes.

Appln. No. 09/214,848
Amd. dated October 8, 2008
Reply to Office Action of March 18, 2008

37(Previously presented). The method according to claim 14, wherein the activated lymphocytes are T-lymphocytes.

38(Previously presented). The method according to claim 13, wherein the viral infection is a herpes group viral infection.

Claim 39 (Cancelled).